Categories: News

Leafbuyer Technologies, Inc. Announces Q3 Results: 46% increase in Quarterly Revenue

Financial Highlights:

  • Quarterly Revenue rose to $984,000 from $672,000 in the third quarter of fiscal year 2021
  • Gross Profit increased to $292,682 from $171,331 in the same period
  • Operating Expenses decreased to $513,469 from $600,733
  • Gross Margins increased 17%

DENVER, CO / ACCESSWIRE / May 17, 2022 / Leafbuyer Technologies, Inc (OTCQB:LBUY) (“Leafbuyer” or “the Company”) a leading cannabis technology and marketing platform, announced today that quarterly revenue rose 46% year over year in the quarter ending March 31, 2022. The increase reflects the GAAP revenue booked in the quarter versus the same quarter of the previous year.

Kurt Rossner, Chief Executive Officer of Leafbuyer, stated, “Our company continues to post growth that is significantly higher than industry averages. The main goals for the remainder of this year will be to continue rapid growth while additionally increasing margins across all product lines. We have several new product launches on the horizon that are super exciting and will hopefully drive significant growth”.

About Leafbuyer Technologies, Inc.

Leafbuyer Technologies is one of the most comprehensive marketing technology providers in the cannabis industry. Hundreds of cannabis businesses use the Leafbuyer texting and loyalty platform and the Custom App solution to engage with current and potential customers. Leafbuyer.com is a robust online resource for cannabis consumers, and the company’s partnerships with other websites have created a national network of cannabis deals and information that reaches millions of consumers every month.

Learn more at http://www.tech.leafbuyer.com

Contact:

Leafbuyer Technologies, Inc.
Vida Almich 720.427.3927
vida@leafbuyertech.com

Cautionary Statement Regarding Forward-Looking Information Safe Harbor Statement

This press release may contain forward-looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in the forward-looking statements due to several factors detailed from time to time in our filings with the Securities and Exchange Commission. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings.

SOURCE: Leafbuyer Technologies, Inc.

View source version on accesswire.com:
https://www.accesswire.com/701712/Leafbuyer-Technologies-Inc-Announces-Q3-Results-46-increase-in-Quarterly-Revenue

Staff

Recent Posts

BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs

An In-Depth Analysis of Digital Sound Frequency Programs, Binaural Beats Research, and Key Considerations for…

6 hours ago

Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research…

6 hours ago

How Does Ozempic Work For Weight Loss? Best Weight Loss Supplement Launch By PhenQ

Ozempic for Weight Loss: Does It Work and Is It Safe? Read PhenQ Details –…

6 hours ago

Best NAD+ Injection for 2026: Sprout Health Lists Compounded NAD+ at $149 First Month as Telehealth Longevity Programs Expand

Prescription NAD+ Injection Access, At-Home Administration Models, Compounding Standards, and What Consumers Should Know Before…

6 hours ago

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

1 day ago